21 May 2013
Keywords: cephalon, plans, file, treanda, nda, 3rd, qtr
Article | 09 July 2007
US biopharmaceutical firm Cephalon says that, based on positive results from a European Phase III study, it plans to file ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
9 July 2007
20 May 2013
© 2013 thepharmaletter.com